Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease

Paolo Verdecchia, MD; Peter Sleight, MD; Giuseppe Mancia, MD; Robert Fagard, MD, PhD; Bruno Trimarco, MD; Roland E. Schmieder, MD; Jae-Hyung Kim, MD; Garry Jennings, MBBS, PhD; Petr Jansky, MD; Jyh-Hong Chen, MD; Lisheng Liu, MD; Peggy Gao, MSc; Jeffrey Probstfield, MD; Koon Teo, MD; Salim Yusuf, MD, DPhil, FRCPC; for the ONTARGET/TRANSCEND Investigators

Background—Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown.

Methods and Results—In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n = 23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n = 5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P = 0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79; P = 0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01; P = 0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02; P = 0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07).

Conclusions—In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone. (Circulation. 2009; 120:1380-1389.)

Key Words: angiotensin • electrocardiography • epidemiology • hypertrophy • prognosis

Left ventricular hypertrophy (LVH) is a reversible determinant of cardiovascular risk, and its diagnosis may influence the therapeutic strategy.1 Echocardiography is more sensitive than ECG for the detection of LVH,2 but it is more expensive and dependent on geometrical assumptions that could reduce accuracy and reproducibility.3 Standard 12-lead ECG is recommended for the diagnosis of LVH in hypertensive subjects.1,4 LVH by ECG is a powerful predictor of

Received December 5, 2008; accepted July 22, 2009.
From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences, University Federico II, Naples, Italy (B.T.); Department of Nephrology and Hypertension, Friedrich Alexander University, Erlangen, Germany (R.E.S.); Department of Cardiology, St Paul’s Hospital, Catholic University of Korea, Division of Cardiology, Seoul, South Korea (J.-H.K.); Baker IDI Heart and Diabetes Institute, Melbourne, Australia (G.J.); University Hospital Motol, Department of Cardiovascular Surgery, Prague, Czech Republic (P.J.); National Cheng Kung University Medical College, Division of Cardiology, Department of Medicine, Tainan, Taiwan (J.-H.C.); Chinese Academy of Medical Sciences, Department of Hypertension, Fu Wai Hospital, Beijing, China (L.L.); and University of Washington, School of Public Health, Seattle (J.P.).
Correspondence to Paolo Verdecchia, MD, McMaster University, Population Health Research Institute, 237 Barton St E, Hamilton, ON L8L2X2 Canada. E-mail verdec@tin.it
© 2009 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.109.865774
cardiovascular morbidity and mortality in the general population and in selected groups of patients.

**Clinical Perspective on p 1389**

ECG is also a diagnostic tool to detect serial changes in LVH. Several antihypertensive drugs, including diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), may cause regression of ECG LVH. ACE inhibitors may not completely block the production of angiotensin II, which is involved in the pathogenesis of LVH. Therefore, ARBs could differ from ACE inhibitors, and the combination of an ACE inhibitor and an ARB might be more effective than either alone. The Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) and Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) enabled testing of these hypotheses. The 2 studies also offered the opportunity to test the relation between LVH and clinical outcome in a large, heterogeneous high-risk population. LVH assessment by ECG was a prespecified outcome of these studies.

**Methods**

Two multinational double-blind trials randomized patients at high cardiovascular risk without known LV systolic dysfunction or congestive heart failure to the ACE inhibitor ramipril, the ARB telmisartan, or their combination (in ONTARGET) or telmisartan versus placebo (in TRANSCEND) in patients unable to tolerate ACE inhibitors. Background therapies were maintained. The median follow-up was 56 months. The main results of the studies have been published. The primary end point was the composite of death resulting from cardiovascular causes, myocardial infarction, stroke, or hospitalization for congestive heart failure. Overall, 31,546 patients were randomized (ONTARGET, 25,620; TRANSCEND, 5926) with history of coronary artery disease, peripheral arterial disease or cerebrovascular disease, or diabetes mellitus complicated by end-organ damage.

The studies were conducted in 733 centers in 40 countries and coordinated by the Population Health Research Institute at McMaster University (Hamilton, Ontario, Canada), where data analysis was undertaken. A central committee blinded to study treatments adjudicated the end points. An independent Data and Safety Monitoring Board monitored the progress of all aspects of the study. The Steering Committee had overall responsibility for interpretation of the results.

The local Ethics Committee in each country approved the study according to local regulations. The study is registered with www.ClinicalTrials.gov, number NCT00153101.

At each of the visits, blood pressure (BP) was measured in duplicate after 3 minutes of rest in subjects in the sitting position with an automated validated device (OMRON, model HEM-757). The average of the 2 readings was used for analysis.

**Definition of LVH**

Participants had a 12-lead ECG at randomization and at years 2 and 5 of follow-up. LVH by ECG was defined in a binary (yes/no) fashion by one or both of the following: (1) sum of the R wave in lead aVL and depth of the S wave in lead V₃ >2.0 mV in women and 2.4 mV in men and (2) strain pattern in I, II, aVL, or V₃ to V₆. Strain pattern was considered present if there was ST-segment depression of at least 0.5 mm and inverted T wave in any lead in the direction opposite the polarity of the QRS. This definition of ECG LVH is simple, is applicable in large populations, and was previously validated.

Copies of ECGs carried out at scheduled visits were forwarded to the coordinating center. An expert reader blinded to the patients’ features (except gender) examined a randomly selected sample of 200 tracings of LVH. There was agreement between the central and investigators’ diagnoses in 182 of 200 tracings (κ statistics = 0.82; P<0.0001). Investigators’ diagnoses of absence of LVH were confirmed on central reading 98% of the time; their diagnoses of LVH were confirmed 84% of the time.

**Data Analysis**

We used SAS 8.2 release (SAS Institute, Cary, NC). Patients with missing ECG data at both follow-up visits (years 2 and 5) were excluded. Continuous data are given as mean ± SD; categorical data are given as frequencies. We compared the characteristics of patients with and without LVH at entry by the Student t test for continuous variables and χ² test for proportions. We tested the degree of agreement between peripheral and central readings of ECG for LVH (absent or present) using κ statistics.

**Comparison Between Treatments**

We used a generalized linear model for repeated categorical measurements (GENMOD routine) to compare telmisartan with placebo in TRANSCEND and to compare the 3 treatment groups in ONTARGET. LVH was categorized as present or absent. Two dummy variables were generated to define the prespecified comparisons of telmisartan versus ramipril and dual renin-angiotensin system blockade versus ramipril in ONTARGET. The resulting odds ratio (OR) reflects the odds of LVH in a given group compared with another group on the total of available follow-up visits (years 2 and 5).

In addition to unadjusted comparisons between treatments, we adjusted for the time of observation and achieved systolic BP during the study as major potential determinants of the differences between the groups in the ECG markers of LVH. Achieved BP was the average of all available BP measurements before an event or censoring, with exclusion of the first visit of the study. In addition, we adjusted for age, history of diabetes mellitus and hypertension, LVH at baseline, and the use of ACE inhibitors or ARBs before the study as further potential confounders. Separate sensitivity analyses were undertaken with the exclusion of patients with complete right or left bundle-branch block and pathological Q waves (≥0.04 second in duration).

We used the Cox proportional-hazard model, counting the first occurrence of any component of the primary outcome, to assess the prognostic impact of LVH at entry defined by voltage criteria, strain criteria, and their combination in the total population. The same approach was used to investigate the impact of new development of LVH on the primary outcome in the subset without LVH at entry and ECG available for LVH assessment at year 2. To this purpose, the binary LVH classification (present, absent) entered the model as a time-varying covariate. In addition to unadjusted estimates, we adjusted for age, gender, history of hypertension, diabetes mellitus, and coronary artery disease. In 2-tailed tests, values of P<0.05 were considered significant.

**Results**

**Baseline Characteristics**

Of the 31,546 randomized patients, 28,508 (90.4%) had a baseline ECG and at least 1 follow-up ECG. The patient flow diagram is shown in Figure 1. The patients with available baseline ECG but missing ECG data at both follow-up visits (n=3038) had a slightly higher systolic BP (143.1 versus 141.5 mm Hg; P<0.01) and a similar diastolic BP (81.9 versus 82.1 mm Hg; P=0.36) than those included in the study. They were also slightly older (68.6 versus 66.3 years;
Figure 1. Patient flow diagram.

For the TRANSCEND study, the prevalence of LVH was 12.7% in the telmisartan group and 12.8% in the placebo group (P=0.86). After 2 and 5 years, it was 10.5% and 12.7% in the telmisartan group and 12.8% and 12.9% with placebo (Figure 2). The odds of LVH on the total of available follow-up visits was 21% lower in the telmisartan group than in the placebo group (OR, 0.79; 95% CI, 0.68 to 0.91; P=0.0017). This difference remained significant after adjustment for time of observation, achieved systolic BP, age, history of diabetes mellitus and hypertension, baseline LVH, and previous treatment with ACE inhibitors and ARBs (OR, 0.76; 95% CI, 0.64 to 0.90; P=0.0015).

Seperate analyses were undertaken to investigate the prevention and regression of LVH. In subjects without LVH at entry (Figure 3), there was a 37% lower risk of LVH at follow-up with telmisartan compared with placebo (OR, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). This remained significant for the ONTARGET study, the reduction in systolic BP from study entry to follow-up averaged 6.6 mm Hg in the telmisartan group and 2.5 mm Hg in the placebo group (mean difference, 4.1 mm Hg; P<0.0001). In ONTARGET, the reduction in systolic BP averaged 6.9 mm Hg in the telmisartan group, 6.0 mm Hg in the ramipril group, and 8.5 mm Hg in the combination group (P<0.0001) compared with ramipril.

Effects of Treatments on LVH

TRANSCEND: Comparison Between Telmisartan and Placebo

Prevalence of LVH at baseline (randomization) was 12.7% in the telmisartan group and 12.8% in the placebo group (P=0.86). After 2 and 5 years, it was 10.5% and 9.8% in the telmisartan group and 12.7% and 12.8% with placebo (Figure 2). The odds of LVH on the total of available follow-up visits was 21% lower in the telmisartan group than in the placebo group (OR, 0.79; 95% CI, 0.68 to 0.91; P=0.0017). This difference remained significant after adjustment for time of observation, achieved systolic BP, age, history of diabetes mellitus and hypertension, baseline LVH, and previous treatment with ACE inhibitors and ARBs (OR, 0.76; 95% CI, 0.64 to 0.90; P=0.0015).

Separate analyses were undertaken to investigate the prevention and regression of LVH. In subjects without LVH at entry (Figure 3), there was a 37% lower risk of LVH at follow-up with telmisartan compared with placebo (OR, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). This remained significant.

P<0.01) and more frequently female (33.6% versus 29.3%; P<0.01) than those included. In TRANSCEND, patients excluded because of missing ECG data were balanced across the 2 treatment groups by age (P=0.05), sex (P=0.33), smoking (P=0.19), history of diabetes mellitus (P=0.48) and coronary artery disease (P=0.49), and systolic (P=0.67) and diastolic BPs (P=0.06). In ONTARGET, patients excluded because of missing ECG data were also balanced across the treatment groups by age (P=0.88), sex (P=0.31), smoking (P=0.72), history of diabetes mellitus (P=0.51) and coronary artery disease (P=0.15), and systolic BP (P=0.11), whereas diastolic BP was slightly lower in the combination group (81 mm Hg) than in each of the other groups (82 mm Hg; P=0.03).

The main characteristics of patients included in the study and divided by the presence or absence of LVH at entry are reported in the Table. A consistent proportion of patients received cardiovascular drugs. At the end of the study, 34% were receiving diuretics, 58% were on β-blockers, 6% took α-1 blockers, 71% were receiving statins, and 36% took aspirin in addition to the study treatments.

Among the 3565 patients with LVH (12.5% of total population), the diagnosis was based on abnormal voltages alone in 51%, strain alone in 25%, and the combination of both in 21%. Information on LVH components was missing in 3% of patients. Atrial fibrillation or flutter was present at entry in 3.1% of patients (4.6% with and 2.9% without LVH; P<0.001). A pattern of right or left bundle-branch block was found in 34.4% of subjects (27.2% with and 36.7% without LVH; P<0.001). Pathological Q waves (≥0.04 second in duration) on anterior leads were present in 30.0% of patients (34.3% with versus 29.4% without LVH; P=0.003). Specifically, the prevalence of LVH was 12.4% in ONTARGET and 12.7% in TRANSCEND.

In TRANSCEND, the reduction in systolic BP from study entry to follow-up averaged 6.6 mm Hg in the telmisartan group and 2.5 mm Hg in the placebo group (mean difference, 4.1 mm Hg; P<0.0001). In ONTARGET, the reduction in systolic BP averaged 6.9 mm Hg in the telmisartan group, 6.0 mm Hg in the ramipril group, and 8.5 mm Hg in the combination group (P<0.0001) compared with ramipril.

Effects of Treatments on LVH

TRANSCEND: Comparison Between Telmisartan and Placebo

Prevalence of LVH at baseline (randomization) was 12.7% in the telmisartan group and 12.8% in the placebo group (P=0.86). After 2 and 5 years, it was 10.5% and 9.8% in the telmisartan group and 12.7% and 12.8% with placebo (Figure 2). The odds of LVH on the total of available follow-up visits was 21% lower in the telmisartan group than in the placebo group (OR, 0.79; 95% confidence interval [CI] 0.68 to 0.91; P=0.0017). This difference remained significant after adjustment for time of observation, achieved systolic BP, age, history of diabetes mellitus and hypertension, baseline LVH, and previous treatment with ACE inhibitors and ARBs (OR, 0.76; 95% CI, 0.64 to 0.90; P=0.0015).

Separate analyses were undertaken to investigate the prevention and regression of LVH. In subjects without LVH at entry (Figure 3), there was a 37% lower risk of LVH at follow-up with telmisartan compared with placebo (OR, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). This remained significant...
after adjustment for time of observation, achieved systolic BP, age, history of diabetes mellitus and hypertension, and previous treatment with ACE inhibitors and ARBs (OR, 0.65; 95% CI, 0.52 to 0.81; \( P < 0.0001 \)). The average reduction in systolic BP from entry to follow-up was greater in the subjects without than in those with future development of LVH (4.8 versus 1.8 mm Hg; \( P < 0.0001 \)). In the subset with LVH at entry, there was in both groups a nonsignificant trend for less LVH at follow-up without significant differences between them (OR, 0.91; 95% CI, 0.70 to 1.19; \( P = 0.49 \)). In this subset, the reduction in systolic BP from entry to follow-up was greater in the subjects with regression than in those with persistence of LVH (6.8 versus 3.9 mm Hg; \( P < 0.0001 \)).

In sensitivity analyses, after the exclusion of patients with right or left bundle-branch block, the odds of LVH at follow-up remained 27% less in the telmisartan group than in the placebo group.

### Table. Main Features of the Population

<table>
<thead>
<tr>
<th></th>
<th>ONTARGET</th>
<th></th>
<th>TRANSCEND</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Overall</td>
<td>LVH Absent</td>
<td>LVH Present</td>
<td>LVH Absent</td>
</tr>
<tr>
<td>n</td>
<td>28508</td>
<td>20282</td>
<td>2883</td>
<td>4661</td>
</tr>
<tr>
<td>Age, y</td>
<td>66.3 (7)</td>
<td>66.1 (7)</td>
<td>66.9 (7)*</td>
<td>66.5 (7)</td>
</tr>
<tr>
<td>Female sex, %</td>
<td>29.3</td>
<td>25.4</td>
<td>32.4*</td>
<td>41.5</td>
</tr>
<tr>
<td>Ethnicity, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>70.7</td>
<td>74.1</td>
<td>65.5*</td>
<td>60.8</td>
</tr>
<tr>
<td>Asian</td>
<td>15.6</td>
<td>14.1</td>
<td>14.0</td>
<td>22.4</td>
</tr>
<tr>
<td>Black</td>
<td>1.7</td>
<td>1.6</td>
<td>3.4*</td>
<td>1.1</td>
</tr>
<tr>
<td>Other</td>
<td>12.0</td>
<td>10.2</td>
<td>17.1*</td>
<td>15.4</td>
</tr>
<tr>
<td>Medical history, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>69.8</td>
<td>66.3</td>
<td>82.7*</td>
<td>74.7</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>36.5</td>
<td>35.5</td>
<td>45.9*</td>
<td>34.2</td>
</tr>
<tr>
<td>Current cigarette smoking</td>
<td>11.8</td>
<td>12.5</td>
<td>11.4</td>
<td>9.6</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>75.1</td>
<td>75.5</td>
<td>72.1*</td>
<td>75.8</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>48.8</td>
<td>49.9</td>
<td>45.5*</td>
<td>46.8</td>
</tr>
<tr>
<td>Coronary revascularization</td>
<td>46.0</td>
<td>48.8</td>
<td>40.0*</td>
<td>43.1</td>
</tr>
<tr>
<td>Stroke or TIA</td>
<td>20.6</td>
<td>20.2</td>
<td>22.0†</td>
<td>20.8</td>
</tr>
<tr>
<td>Occlusive arterial disease</td>
<td>12.5</td>
<td>12.7</td>
<td>14.0</td>
<td>10.3</td>
</tr>
<tr>
<td>Medication use at entry, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>57.7</td>
<td>56.5</td>
<td>65.0*</td>
<td>58.5</td>
</tr>
<tr>
<td>ARBs</td>
<td>12.5</td>
<td>8.3</td>
<td>9.3</td>
<td>29.7</td>
</tr>
<tr>
<td>( \beta )-Blockers</td>
<td>57.9</td>
<td>57.6</td>
<td>58.3</td>
<td>58.6</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>34.4</td>
<td>32.1</td>
<td>39.7*</td>
<td>39.8</td>
</tr>
<tr>
<td>Diuretics</td>
<td>27.9</td>
<td>25.8</td>
<td>36.2*</td>
<td>30.2</td>
</tr>
<tr>
<td>Statins</td>
<td>61.4</td>
<td>64.0</td>
<td>53.1*</td>
<td>58.1</td>
</tr>
<tr>
<td>Aspirin</td>
<td>75.9</td>
<td>76.7</td>
<td>72.1*</td>
<td>75.5</td>
</tr>
<tr>
<td>Physical/laboratory values</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP, mm Hg</td>
<td>141.5 (17)</td>
<td>141.1 (17)</td>
<td>145.8 (17)*</td>
<td>140.3 (16)</td>
</tr>
<tr>
<td>Diastolic BP, mm Hg</td>
<td>82.1 (10)</td>
<td>82.0 (10)</td>
<td>82.9 (11)*</td>
<td>81.7 (10)</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>67.8 (12)</td>
<td>67.6 (12)</td>
<td>68.0 (12)</td>
<td>68.6 (12)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>28.1 (4)</td>
<td>28.1 (4)</td>
<td>28.0 (5)</td>
<td>28.1 (4)</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>96.0 (13)</td>
<td>96.3 (13)</td>
<td>95.7 (13)†</td>
<td>95.1 (13)</td>
</tr>
<tr>
<td>Serum creatinine, mmol/L</td>
<td>93.0 (22)</td>
<td>93.0 (22)</td>
<td>95.8 (23)*</td>
<td>91.5 (22)</td>
</tr>
<tr>
<td>Glucose, mmol/L</td>
<td>6.61 (2.5)</td>
<td>6.59 (2.4)</td>
<td>7.03 (2.9)*</td>
<td>6.43 (2.3)</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>4.96 (1.1)</td>
<td>4.90 (1.1)</td>
<td>5.14 (1.1)*</td>
<td>5.06 (1.2)</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L</td>
<td>1.26 (0.4)</td>
<td>1.26 (0.4)</td>
<td>1.27 (0.5)</td>
<td>1.27 (0.4)</td>
</tr>
<tr>
<td>LDL cholesterol, mmol/L</td>
<td>2.93 (1.0)</td>
<td>2.89 (1.0)</td>
<td>3.12 (1.0)*</td>
<td>2.99 (1.0)</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>1.74 (1.1)</td>
<td>1.72 (1.1)</td>
<td>1.77 (1.1)†</td>
<td>1.79 (1.3)</td>
</tr>
</tbody>
</table>

TIA indicates transient ischemic attack; HDL, high-density lipoprotein; and LDL, low-density lipoprotein. Values are mean (SD) when appropriate.

*\( P < 0.01 \); †\( P < 0.05 \).
pathological Q waves, the odds of LVH at follow-up was 20% less in the telmisartan than in the placebo group \( (P=0.005) \).

**Subgroup Analyses**

The differences between telmisartan and placebo in TRANSCEND (Figure 4) were consistent across several prespecified subgroups.

**ONTARGET: Comparison Between Telmisartan, Ramipril, and Their Combination**

Figure 5 shows the prevalence of LVH at follow-up in the telmisartan, ramipril, and combination groups. LVH decreased from baseline to follow-up in all 3 groups (all \( P<0.001 \)). LVH showed a nonsignificant trend to be less frequent with telmisartan than with ramipril (OR, 0.92; 95% CI, 0.83 to 1.01; \( P=0.07 \)). The odds of LVH during follow-up was also nonsignificantly lower with the combination compared with ramipril (OR, 0.93; 95% CI, 0.84 to 1.02; \( P=0.12 \)). We found no differences in the odds of LVH during the study between the telmisartan group and the combination group (OR, 1.01; 95% CI, 0.91 to 1.12).

**Relation Between LVH and Outcome**

In the total population, the risk of primary outcome during follow-up increased progressively (Figure 6) when the diagnosis of LVH at entry was based on high voltage alone (hazard ratio [HR], 1.41; 95% CI, 1.28 to 1.56; \( P<0.001 \)), strain alone (HR, 1.71; 95% CI, 1.51 to 1.94; \( P<0.001 \)), and their combination (HR, 2.15; 95% CI, 1.90 to 2.44; \( P<0.001 \)) compared with the absence of LVH. Simultaneous adjustment for age, gender, diabetes mellitus, hypertension, and history of coronary artery disease did not change these estimates (all \( P<0.001 \)).

In the subset of patients without LVH at entry, the primary study outcome (composite of death resulting from cardiovascular causes, myocardial infarction, stroke, and congestive heart failure requiring hospitalization) occurred more frequently in association with new-onset LVH at follow-up than in its absence (HR, 1.77; 95% CI, 1.50 to 2.07; \( P<0.0001 \)). The excess risk of primary outcome associated with new-onset LVH did not change after simultaneous adjustment for age, gender, and history of hypertension, diabetes mellitus, and coronary artery disease (HR, 1.67; 95% CI, 1.42 to 1.96; \( P<0.0001 \)). Figure 7 shows the modified Kaplan-Maier

---

**Figure 2.** Prevalence of LVH at baseline (randomization) and after 2 and 5 years in the groups randomized to telmisartan or placebo.

**Figure 3.** New development of LVH at 2 and 5 years in patients randomized to telmisartan or placebo.
curves reporting the incidence of primary outcome event in association with new-onset LVH.

Discussion

Our study on a widely heterogeneous population of subjects at high cardiovascular risk provides the following novel evidence. First, compared with placebo, which actually consisted of a group of subjects intensively treated with drugs other than those blocking the renin-angiotensin system, telmisartan was more effective in preventing the appearance of ECG-based LVH, whereas LVH regression was not affected. The effect on new-onset LVH remained significant when data were adjusted for factors including the treatment-induced reduction in BP and the previous exposure to blockers of the renin-angiotensin system. Second, in subjects randomized to telmisartan or to telmisartan combined with ramipril, the chance of LVH on follow-up was slightly lower than in subjects randomized to ramipril, although the differences were not statistically significant. The issues raised by these data are discussed below separately.

Figure 4. Odds of LVH in prespecified subgroups allocated to telmisartan or placebo. SBP indicates systolic BP; TIA, transient ischemic attack; and ACEI, ACE inhibitor.

Figure 5. Prevalence of LVH at baseline (randomization) and after 2 and 5 years in the groups randomized to telmisartan, ramipril, or their combination.
Telmisartan Versus Placebo

Although 21% fewer patients experienced LVH with telmisartan than with placebo in TRANSCEND, this difference did not translate into a difference in congestive heart failure, a complication predicted by LVH and its changes over time.11,18 Similarly, although 8% fewer patients experienced LVH with telmisartan than with ramipril in ONTARGET, this difference did not affect outcome. The modest reduction in BP at follow-up could explain the lack of significant differences between telmisartan and placebo on LVH regression, in contrast to the 37% lower risk of new-onset LVH in the telmisartan group compared with the placebo group. Of note, new-onset LVH was associated with a significantly higher risk of the primary study outcome in the total population regardless of randomized treatment. These findings extend to a mixed high-risk population the adverse prognostic impact of serial worsening in the ECG voltages or repolarization markers of LVH previously noted by the Framingham investigators in the general population.5 A further hypothesis to consider is that an improvement in the ECG markers of LVH might be less likely to occur in high-risk patients with severe atherosclerotic vascular disease and organ damage. In these patients, LVH regression might not translate to the same prognostic benefit as in the general population5 or in subjects with hypertension.18,19 The evidence provided by Okin and coworkers20 that the prognostic value of LVH regression is reduced in hypertensive patients with LVH and diabetes mellitus compared with those with LVH without diabetes mellitus is consistent with the above hypothesis.

Telmisartan Versus Ramipril

Telmisartan was associated with a statistically nonsignificant lower chance of LVH during follow-up compared with ramipril (−8%). This was a posthoc analysis because the direct comparison between telmisartan and ramipril was not prespecified.15 In the few studies available, LVH regression was comparable with ACE inhibitors and ARBs.21,22 In a subset of 297 subjects included in ONTARGET who were studied with magnetic resonance imaging at baseline and...
after 2 years, LV mass decreased to a similar extent in the 3 groups.\textsuperscript{23} LVH was absent in almost all these subjects at baseline (LV mass, 36.5 g/m\textsuperscript{2}).\textsuperscript{23}

One mechanism potentially leading to a greater LVH regression with an ARB compared with an ACE inhibitor might be the overactivation of AT2 subtype receptors by angiotensin II during treatment with an ARB. AT2 subtype receptors are upregulated in hypertrophic hearts.\textsuperscript{24} These receptors might trigger antiproliferative and antifibrotic effects, opposing AT1 receptor stimulation of cardiac hypertrophy and remodeling.\textsuperscript{25} Transgenic animals overexpressing AT2 subtype receptors showed less fibrosis than control animals in a model of occlusion/reperfusion of the left anterior descending artery.\textsuperscript{26}

**Telmisartan Plus Ramipril Versus Ramipril**

Patients allocated to the combination of telmisartan and ramipril showed a slightly lower, although not statistically significant, probability of LVH compared with ramipril alone. Hemodynamic and humoral factors associated with the decline in renal function, which was more pronounced in patients exposed to the dual blockade of renin-angiotensin system than in those treated with ramipril or telmisartan alone,\textsuperscript{27} might have limited the benefit of dual renin-angiotensin system blockade on LVH. Several mechanisms, including secondary hyperparathyroidism,\textsuperscript{28} abnormal vitamin D metabolism,\textsuperscript{29} activation of cardiac mineral corticoid receptors,\textsuperscript{30} and anemia,\textsuperscript{31} may be involved in the pathogenesis of LVH when renal function declines. ACE inhibitors, by inhibiting angiotensin II generation, could also limit the stimulating effect by angiotensin II on AT2 subtype receptors during treatment with an ARB, thereby limiting their protective impact on LVH.

**Voltage and Repolarization Markers of LVH and Clinical Outcome**

We found a progressive increase in the risk of primary study outcome when the diagnosis of LVH at entry was based on high voltages alone, strain alone, or their combination. Voltage-only LVH did not predict an increased risk of cardiovascular disease in general population studies.\textsuperscript{32} In the Heart Outcomes Prevention Evaluation (HOPE) study, which examined high-risk patients comparable to those enrolled in the present study, LVH defined by voltage alone was an independent predictor of outcome.\textsuperscript{33} In general population studies, which include a significant proportion of young and healthy subjects, elevated ECG voltages not accompanied by repolarization abnormalities might be more likely to identify relatively low-risk individuals characterized by less attenuation of voltages from the heart to the skin surface because of several potential factors, including a low body mass index and a younger age. Conversely, elevated ECG voltages could be more specific for true LVH in patients at higher risk. This issue warrants further investigation. The strain pattern was associated with a further increase in the risk of primary outcome. Concentric LVH has been associated with subendocardial ischemia both in the presence and in the absence of coronary artery disease.\textsuperscript{34} Frequency of strain increases in parallel with LV mass on echocardiography.\textsuperscript{35}

**Limitations**

Diagnosis of LVH was based on ECG, which is less sensitive than echocardiography.\textsuperscript{2} To simplify the calculation and obtain an adequate diagnostic performance, diagnosis of LVH by ECG was predefined by an index that incorporates voltage and repolarization criteria.\textsuperscript{17} Diagnosis of LVH was binary (yes/no), not quantitative. The product of ECG voltages (Cornell voltage) by QRS duration, which requires digital acquisition of tracings, provides an accurate estimate of LVH with the assessment of its changes in a quantitative fashion.\textsuperscript{36} Additionally, local investigators interpreted the ECGs using explicit prespecified criteria. Lack of precision in the ECG reading would likely be random and would not systematically bias the results. The degree of agreement between the central and investigators’ diagnoses of LVH in a randomly selected sample of 200 tracings was good, with a $\kappa$ statistic of 0.82. $\kappa$ Statistics between 0.61 and 0.80 have been defined as substantial, and those $>0.80$ have been defined as almost perfect.\textsuperscript{37} The peripheral reading of ECGs and the simple diagnostic criteria for LVH should increase the clinical applicability of our study.

**Conclusions**

Telmisartan was superior to placebo in preventing LVH in individuals at high vascular risk. This effect was independent of office BP changes. Office BP, however, may not reflect the BP burden over 24 hours. An ONTARGET/TRANSCEND substudy with 24-hour ambulatory BP monitoring\textsuperscript{15} will provide more insight into this issue. Telmisartan showed a trend to be slightly, but not significantly, more effective than ramipril in reducing ECG LVH, and the combination of the 2 drugs did not provide any additional benefit. The different pattern in LVH changes did not translate into a prognostic benefit, possibly because of the inadequate time for translation of the gradual LVH reduction into harder clinical events. These findings substantiate the efficacy of telmisartan in preventing the appearance of LVH in a wide population of patients at increased vascular risk.

**Source of Funding**

This study was supported by Boehringer-Ingelheim.

**Disclosures**

Dr. Verdecchia, Sleight, Mancia, Fagard, Trimarco, Schneider, Jennings, Probstfield, Teo, and Yusuf received consulting, lecture fees, and research grants from Boehringer Ingelheim and from other companies that manufacture ARBs. Dr. Verdecchia was also supported by the nonprofit foundation Fondazione Umbra Cuore e Ipertensione, Perugia, Italy. The other authors report no conflicts.

**References**


CLINICAL PERSPECTIVE
In patients with high vascular risk resulting from coronary artery disease, stroke, peripheral occlusive disease, or diabetes mellitus, the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular (LV) hypertrophy (LVH) is unknown. In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of angiotensin-converting enzyme inhibitors were randomly assigned to ramipril, telmisartan, or their combination. In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), telmisartan was more effective than placebo in preventing the appearance of ECG-based LVH (odds ratio, 0.63; 95% confidence interval, 0.51 to 0.79; P=0.0001), whereas LVH regression was not affected. In ONTARGET, LVH occurred slightly less frequently with telmisartan and the combination than with ramipril, but differences between groups were not significant. The risk of primary outcome during follow-up increased progressively when the diagnosis of LVH at entry was based on high voltage alone, strain alone, and their combination compared with the absence of LVH. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% confidence interval, 1.50 to 2.07). Overall, these results are consistent with the main results of the study. The different pattern in LVH changes did not translate into a prognostic benefit, possibly because of the inadequate time for translation of the gradual LVH reduction into harder clinical events. These findings substantiate the efficacy of telmisartan in preventing the appearance of LVH in patients at increased vascular risk. The data also suggest that LVH defined on ECG by the combination of elevated voltages and strain is associated with a markedly increased risk in these patients.
Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease

Paolo Verdecchia, Peter Sleight, Giuseppe Mancia, Robert Fagard, Bruno Trimarco, Roland E. Schmieder, Jae-Hyung Kim, Garry Jennings, Petr Jansky, Jyh-Hong Chen, Lisheng Liu, Peggy Gao, Jeffrey Probstfield, Koon Teo and Salim Yusuf
for the ONTARGET/TRANSCEND Investigators

Circulation. 2009;120:1380-1389; originally published online September 21, 2009; doi: 10.1161/CIRCULATIONAHA.109.865774

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/120/14/1380

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/